[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566607":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Fycompa",null,[12],"Other: No Intervention",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","No Intervention","This is a non-interventional study.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Eisai Inquiry Service","CONTACT","0120-419-497","eisai-chiken_hotline@hhc.eisai.co.jp",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"1","RECRUITING","Tokyo","Japan","JP",{"type":33,"coordinates":34},"Point",[35,36],139.69171,35.6895,{"lat":36,"lon":35},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100566607","a-study-to-evaluate-the-safety-of-fycompa-injection-in-participants-with-partial-onset-seizures-or-primary-generalized-tonic--clonic-seizures-100566607",false,"NCT06657378","A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures","A Multicenter, Postmarketing Observational (Noninterventional) Study to Evaluate the Safety of Fycompa for Injection in Patients With Partial-Onset Seizures (Including Secondarily Generalized Seizures) (Age 4 Years or Older) or Primary Generalized Tonic- Clonic Seizures (Age 12 Years or Older)","Inclusion Criteria:\n\n* Participants with epilepsy who received the Fycompa for injection for the first time will be included.\n\nExclusion Criteria:\n\n* The exclusion criteria will not be specified in particular because this survey will be conducted in daily clinical practice.","ALL","4 Years",{"count":50,"type":51},110,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures \\[including secondarily generalized seizures\\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).",[55,56],"Partial-Onset Seizures","Primary Generalized Tonic-clonic Seizures",[58,59,9],"Seizures","Secondarily Generalized Seizures","2026-06-30",{"date":62,"type":63},"2026-07-01","ACTUAL",{"date":65,"type":63},"2024-11-18",{"date":67,"type":51},"2028-06-15",{"name":69,"class":6},"Eisai Co., Ltd.",1]